February 6, 2026
Clinical Updates
Darzalex Faspro® (daratumumab and hyaluronidase-fihj) – Expanded indication
January 27, 2026 - J&J announced the FDA approval of Darzalex Faspro (daratumumab and hyaluronidase-fihj), for the treatment of adult patients with multiple myeloma in combination with bortezomib, lenalidomide, and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant (ASCT).
Drug Approvals
Yuvezzi™ (carbachol/brimonidine tartrate) – New drug approval
January 28, 2026 - Tenpoint Therapeutics announced the FDA approval of Yuvezzi (carbachol/brimonidine tartrate), for the treatment of presbyopia in adults.